Published in AIDS Weekly, December 18th, 1995
Unlike natural polyclonal antibodies produced by humans or animals inoculated with antigens, MAbs are tailored to recognize only highly specific epitopes. MAbs represent an exciting new frontier in AIDS therapy because they can do - at least in the test tube - something the human immune response can rarely if ever achieve: neutralize widely different strains of HIV.
Diane Wara of the University of California, San Francisco, and George McSherry of the University of Medicine and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.